Analysis: Regulatory pathway for biosimilars is still unclear

11/2/2010 | Reuters

Although FDA officials have started discussing the creation of a regulatory pathway for approving biosimilars, the agency has not set a deadline for the implementation of such a system, and it could take at least five years for such drugs to reach the market, experts said. "People will be frustrated. It's not going to be a clear pathway for everything," said Ian Spatz, a policy consultant in Washington, D.C., and a former executive at Merck & Co.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI